M&A Deal Summary

Ginkgo Bioworks Acquires StrideBio - AAV Capsid Discovery and Engineering Platform Assets

On April 5, 2023, Ginkgo Bioworks acquired life science company StrideBio - AAV Capsid Discovery and Engineering Platform Assets from StrideBio

Acquisition Highlights
  • This is Ginkgo Bioworks’ 7th transaction in the Life Science sector.
  • This is Ginkgo Bioworks’ 7th transaction in the United States.
  • This is Ginkgo Bioworks’ 1st transaction in North Carolina.

M&A Deal Summary
Date 2023-04-05
Target StrideBio - AAV Capsid Discovery and Engineering Platform Assets
Sector Life Science
Buyer(s) Ginkgo Bioworks
Sellers(s) StrideBio
Deal Type Divestiture

Target

StrideBio - AAV Capsid Discovery and Engineering Platform Assets

Research Triangle Park, North Carolina, United States
StrideBio's AAV Capsid Discovery and Engineering Platform Assets includes R&D services for gene therapy manufacturing across capsid, payload, and cell line optimization

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ginkgo Bioworks

Boston, Massachusetts, United States
Category Company
Founded 2008
Sector Life Science
DESCRIPTION

Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks was established in 2008 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 10 of 14
Sector (Life Science) 7 of 9
Type (Divestiture) 1 of 3
State (North Carolina) 1 of 1
Country (United States) 7 of 11
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-04 Circularis

Oakland, California, United States

Circularis is a biotechnology company with a proprietary circular RNA and promoter screening platform. The company's novel biology has enabled new scales of experimental methods to help customers make advancements in gene therapy and the treatment of rare diseases. Its advanced understanding of circular RNA across multiple cell types and organisms has guided the design toward a range of novel circular RNA materials for use in the growing field of RNA therapeutics. Circularis is based in Oakland, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-28 Proof Diagnostics

Cambridge, Massachusetts, United States

Proof Diagnostics is a life sciences tools, diagnostics, and computational discovery company that uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases. Proof Diagnostics was founded in 2020 and is based in Cambridge, Massachusetts.

Buy -

Seller(S) 1

SELLER

StrideBio

Research Triangle Park, North Carolina, United States
Category Company
Sector Life Science
DESCRIPTION

StrideBio is a gene therapy company. StrideBio is based in Research Triangle Park, North Carolina.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 1 of 1
Year (2023) 1 of 1
Mergr

Product

Company

Legal